Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
genetics
non‐Hodgkin lymphoma
prognostic factors
radiotherapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
14
05
2024
accepted:
28
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
7
8
2024
Statut:
aheadofprint
Résumé
Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Leukemia and Lymphoma Society of Canada
ID : 513421
Organisme : Hold 'em for Life Oncology Fellowship
ID : N/A
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27(suppl 5):v83–v90.
Kuruvilla J, Assouline S, Hodgson D, MacDonald D, Stewart D, Christofides A, et al. A Canadian evidence‐based guideline for the first‐line treatment of follicular lymphoma: joint consensus of the lymphoma Canada scientific advisory board. Clin Lymphoma Myeloma Leuk. 2015;15(2):59–74.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B‐Cell Lymphomas, V.5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [November 1, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org.
Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F‐FDG PET‐CT: a collaborative study by ILROG. Blood. 2019;133(3):237–245.
Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long‐term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–3806.
McNamara C, Montoto S, Eyre TA, Ardeshna K, Burton C, Illidge T, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191(3):363–381.
MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, et al. Randomized trial of systemic therapy after involved‐field radiotherapy in patients with early‐stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918–2925.
Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R‐CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653. e3.
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first‐line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population‐based registry. Lancet Oncol. 2015;16(9):1111–1122.
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, et al. Rosenwald a; German low grade lymphoma study group (GLSG). Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30(4):854–860.
Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, et al. Localized‐ and advanced‐stage follicular lymphomas differ in their gene expression profiles. Blood. 2020;135(3):181–190.
Hellmuth JC, Louissaint A Jr, Szczepanowski M, Haebe S, Pastore A, Alig S, et al. Duodenal‐type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood. 2018;132(16):1695–1702.
Los‐de Vries GT, Stevens WBC, van Dijk E, Langois‐Jacques C, Clear AJ, Stathi P, et al. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV. Blood Adv. 2022;6(18):5482–5493.
Van der Auwera GA, O'Connor BD. Genomics in the cloud: using Docker, GATK, and WDL in Terra. (‘O'Reilly Media, Inc.’ 2020.
Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling somatic SNVs and Indels with Mutect2. Preprint at https://doi.org/10.1101/861054
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Genome Aggregation Database Consortium; Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443.
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high‐throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
Dreval K, Hilton LK, Cruz M, Shaalan H, Ben‐Neriah S, Boyle M, et al. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023;142(6):561–573.
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020;10(3):440–459.
Kalmbach S, Grau M, Zapukhlyak M, Leich E, Jurinovic V, Hoster E, et al. Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms. Leukemia. 2023;37(10):2058–2065.
Russler‐Germain DA, Krysiak K, Ramirez C, Mosior M, Watkins MP, Gomez F, et al. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Adv. 2023;7(18):5524–5539.
Gao F, Liu H, Meng X, Liu J, Wang J, Yu J, et al. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma. Br J Haematol. 2023;202(6):1151–1164.